Karthikeya Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-12-2024
- Paid Up Capital ₹ 1.00 M
as on 15-12-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 9.24%
(FY 2022)
- Profit 14.78%
(FY 2022)
- Ebitda 137.43%
(FY 2022)
- Net Worth 3.18%
(FY 2022)
- Total Assets 2.24%
(FY 2022)
About Karthikeya Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Karthikeya Life Sciences Private Limited India is Nadipally Radhakrishna as CEO. Nadipally Radhakrishna, Nadipally Rani, and Telukuntla Madhuri serve as directors at the Company.
- CIN/LLPIN
U24100TG2015PTC098558
- Company No.
098558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Karthikeya Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nadipally Radhakrishna  | CEO | 30-Nov-2021 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nadipally Radhakrishna | Director and Ceo | 05-Jul-2021 | Current |
| Nadipally Rani | Director | 20-Apr-2015 | Current |
| Telukuntla Madhuri | Whole-Time Director | 20-Apr-2015 | Current |
Financial Performance of Karthikeya Life Sciences.
Karthikeya Life Sciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 9.24% increase. The company also saw a substantial improvement in profitability, with a 14.78% increase in profit. The company's net worth moved up by a moderate rise of 3.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karthikeya Life Sciences?
In 2019, Karthikeya Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Karthikeya Life Sciences?
Unlock and access historical data on people associated with Karthikeya Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karthikeya Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karthikeya Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
